Seeking Alpha

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead ...

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it ...
Nasdaq

TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First ...

BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
Seeking Alpha

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus ...

BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further ...

TransCode Therapeutics任命Jack E. Stover为董事会成员

波士顿 - 专注于免疫肿瘤学和针对晚期癌症的RNA治疗的临床阶段公司 TransCode Therapeutics, Inc. (NASDAQ:RNAZ) 周一宣布任命Jack E. Stover加入其董事会。这家市值仅为726万美元的微型市值公司目前交易价格为每股7.92美元，根据 InvestingPro 分析显示，尽管该公司年初至今已损失超过91%的价值，但其股价仍低于其公允价值。
Nasdaq

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic ...

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a ...
Eagle-Tribune

TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation

Two clinical trial sites activated Patient enrollment expected this quarter Trial designed to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, Aug. 15, 2024 (GLOBE NEWSWIRE ...
Business Insider

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
Business Insider

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 ...

BOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
KELOLAND News

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate ...

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode ...
FOX31 Denver

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its ...

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...
Morningstar

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million ...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...